Endpoints News 直播：美国中期选举对生物医药行业意味着什么

🗳️ Live Wednesday at 1:30 pm ET! 🎙️ It’s Election Day in the US, and the results could have wide-ranging implications for biotech and pharma. Democratic control of Congress would mean new movement around drug pricing policy and scrutiny of the Trump administration’s “most favored nation” deals. It could mean investigations into HHS Secretary Robert F. Kennedy Jr., shifts in China policy, changes to funding rules for US research, plus more policy and people turbulence at the FDA. Tomorrow at 1:30 pm ET, Endpoints News Senior Reporter Max Bayer and I will be joined by frequent Post-Hoc Live guest Nick Shipley, an expert on biopharma policy and politics. We’ll break down what the midterms mean for biopharma and how the industry will navigate Washington over the next few years. Join us on YouTube (and set a Google or Outlook calendar alert for a reminder). See you after the votes, — Drew Armstrong, Executive Editor